Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer

The hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer subtype accounts for most early and metastatic breast cancer (MBC) cases. HR-positive/HER2-negative MBC is characterized by a relatively prolonged, although variable, disease course and substantial intertumoral and intratumoral heterogeneity. Although endocrine-based therapies remain the cornerstone of treatment, nearly all patients eventually develop resistance, which is increasingly addressed with biologically targeted agents and newer-generation cytotoxic drugs. This review summarizes the current understanding of HR-positive/HER2-negative MBC biology, highlighting mechanisms of intrinsic and acquired…

• NI
  National Institutes of Health

  Award: P30CA016672
• UO
  University of Texas MD Anderson Cancer Center

  Award: P30CA016672
• NC
  National Cancer Institute

  Award: P30CA016672